(ITP) Interparfums - Overview
Stock: Fragrances, Cosmetics, Perfume, Skincare, Beauty
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.24% |
| Yield on Cost 5y | 4.49% |
| Yield CAGR 5y | 20.25% |
| Payout Consistency | 92.9% |
| Payout Ratio | 62.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 30.8% |
| Relative Tail Risk | -7.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.12 |
| Alpha | -39.16 |
| Character TTM | |
|---|---|
| Beta | 0.325 |
| Beta Downside | 0.540 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.61% |
| CAGR/Max DD | -0.33 |
Description: ITP Interparfums January 11, 2026
Interparfums SA (ticker ITP) designs, manufactures and distributes licensed perfumes and cosmetics for a portfolio of luxury fashion and jewelry houses-including Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lanvin, Lacoste, Montblanc, Moncler, Rochas, S.T. Dupont and Van Cleef & Arpels-across Europe, the Americas, Africa, the Middle East and Asia. The firm operates through two reporting segments, Fragrances and Fashion, and reaches end-customers via wholly-owned subsidiaries, joint ventures, independent distributors, cosmetics subsidiaries and duty-free operators.
Founded in 1982 and headquartered in Paris, Interparfums SA is a subsidiary of Interparfums Inc. In FY 2023 the company generated roughly €410 million in revenue, with an operating margin around 6 %-consistent with the high-margin profile of the luxury fragrance niche. The global fragrance market is projected to grow at a 3-4 % CAGR through 2027, driven by rising disposable income in emerging Asian markets and an accelerating shift toward e-commerce distribution channels, both of which are material to Interparfums’ growth outlook.
Key economic sensitivities include currency exposure (particularly EUR/USD and EUR/JPY), licensing royalty structures tied to brand performance, and consumer sentiment toward premium personal-care goods. Monitoring these drivers alongside the company’s cash-conversion cycle and debt-to-equity ratio (~0.5×) can help gauge its resilience in a volatile macro environment.
For a deeper quantitative view of ITP’s valuation metrics, the ValueRay platform offers a concise, data-driven dashboard worth checking.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 237.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -3.34 > 1.0 |
| NWC/Revenue: 23.53% < 20% (prev 27.88%; Δ -4.35% < -1%) |
| CFO/TA 0.10 > 3% & CFO 99.9m > Net Income 237.8m |
| Net Debt (89.8m) to EBITDA (366.2m): 0.25 < 3 |
| Current Ratio: 3.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (83.8m) vs 12m ago 10.34% < -2% |
| Gross Margin: 65.71% > 18% (prev 0.65%; Δ 6505 % > 0.5%) |
| Asset Turnover: 156.9% > 50% (prev 123.7%; Δ 33.26% > 0%) |
| Interest Coverage Ratio: 28.70 > 6 (EBITDA TTM 366.2m / Interest Expense TTM 11.4m) |
Altman Z'' 7.17
| A: 0.36 (Total Current Assets 533.7m - Total Current Liabilities 171.6m) / Total Assets 992.5m |
| B: 0.07 (Retained Earnings 73.1m / Total Assets 992.5m) |
| C: 0.33 (EBIT TTM 328.1m / Avg Total Assets 980.4m) |
| D: 2.18 (Book Value of Equity 679.6m / Total Liabilities 311.7m) |
| Altman-Z'' Score: 7.17 = AAA |
Beneish M -2.65
| DSRI: 1.01 (Receivables 181.1m/139.5m, Revenue 1.54b/1.20b) |
| GMI: 1.00 (GM 65.71% / 65.49%) |
| AQI: 1.04 (AQ_t 0.29 / AQ_t-1 0.28) |
| SGI: 1.28 (Revenue 1.54b / 1.20b) |
| TATA: 0.14 (NI 237.8m - CFO 99.9m) / TA 992.5m) |
| Beneish M-Score: -2.65 (Cap -4..+1) = A |
What is the price of ITP shares?
Over the past week, the price has changed by -1.71%, over one month by +0.16%, over three months by -7.55% and over the past year by -32.92%.
Is ITP a buy, sell or hold?
What are the forecasts/targets for the ITP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.6 | 17.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.5 | -2.9% |
ITP Fundamental Data Overview February 03, 2026
P/E Trailing = 15.1667
P/E Forward = 16.2602
P/S = 2.3564
P/B = 3.1446
Revenue TTM = 1.54b EUR
EBIT TTM = 328.1m EUR
EBITDA TTM = 366.2m EUR
Long Term Debt = 118.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 49.5m EUR (from shortTermDebt, last quarter)
Debt = 176.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 89.8m EUR (from netDebt column, last quarter)
Enterprise Value = 2.22b EUR (2.13b + Debt 176.9m - CCE 90.1m)
Interest Coverage Ratio = 28.70 (Ebit TTM 328.1m / Interest Expense TTM 11.4m)
EV/FCF = 27.00x (Enterprise Value 2.22b / FCF TTM 82.2m)
FCF Yield = 3.70% (FCF TTM 82.2m / Enterprise Value 2.22b)
FCF Margin = 5.34% (FCF TTM 82.2m / Revenue TTM 1.54b)
Net Margin = 15.45% (Net Income TTM 237.8m / Revenue TTM 1.54b)
Gross Margin = 65.71% ((Revenue TTM 1.54b - Cost of Revenue TTM 527.6m) / Revenue TTM)
Gross Margin QoQ = 65.91% (prev 65.60%)
Tobins Q-Ratio = 2.24 (Enterprise Value 2.22b / Total Assets 992.5m)
Interest Expense / Debt = 1.97% (Interest Expense 3.48m / Debt 176.9m)
Taxrate = 25.40% (24.9m / 97.9m)
NOPAT = 244.8m (EBIT 328.1m * (1 - 25.40%))
Current Ratio = 3.11 (Total Current Assets 533.7m / Total Current Liabilities 171.6m)
Debt / Equity = 0.26 (Debt 176.9m / totalStockholderEquity, last quarter 679.6m)
Debt / EBITDA = 0.25 (Net Debt 89.8m / EBITDA 366.2m)
Debt / FCF = 1.09 (Net Debt 89.8m / FCF TTM 82.2m)
Total Stockholder Equity = 661.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 24.25% (Net Income 237.8m / Total Assets 992.5m)
RoE = 35.97% (Net Income TTM 237.8m / Total Stockholder Equity 661.0m)
RoCE = 42.12% (EBIT 328.1m / Capital Employed (Equity 661.0m + L.T.Debt 118.2m))
RoIC = 30.36% (NOPAT 244.8m / Invested Capital 806.3m)
WACC = 6.68% (E(2.13b)/V(2.31b) * Re(7.11%) + D(176.9m)/V(2.31b) * Rd(1.97%) * (1-Tc(0.25)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 5.04%
[DCF Debug] Terminal Value 85.34% ; FCFF base≈94.3m ; Y1≈112.6m ; Y5≈177.9m
Fair Price DCF = 48.04 (EV 4.11b - Net Debt 89.8m = Equity 4.02b / Shares 83.7m; r=6.68% [WACC]; 5y FCF grow 20.70% → 2.90% )
Revenue Correlation: 64.85 | Revenue CAGR: 38.12% | SUE: 1.50 | # QB: 1
EPS next Year (2026-12-31): EPS=1.41 | Chg30d=-0.037 | Revisions Net=+2 | Growth EPS=-9.2% | Growth Revenue=-0.1%